{
    "root": "8f31581c-123d-4850-b453-dce159d77e72",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Cyclophosphamide",
    "value": "20250130",
    "ingredients": [
        {
            "name": "CYCLOPHOSPHAMIDE",
            "code": "8N3DW7272P"
        }
    ],
    "indications": "cyclophosphamide injection alkylating indicated treatment adults pediatric patients : • malignant diseases : malignant lymphomas : hodgkin ’ disease , lymphocytic lymphoma , mixed-cell type lymphoma , histiocytic lymphoma , burkitt ’ lymphoma ; multiple myeloma , leukemias , mycosis fungoides , neuroblastoma , adenocarcinoma ovary , retinoblastoma , breast carcinoma ( 1.1 ) • minimal change nephrotic syndrome pediatric patients : biopsy proven minimal change nephrotic syndrome patients failed adequately respond unable tolerate adrenocorticosteroid therapy ( 1.2 ) limitations : safety effectiveness treatment nephrotic syndrome adults renal disease established . ( 1.2 )",
    "contraindications": "immediately cyclophosphamide injection , administer adequate amounts fluid reduce risk urinary tract toxicity ( 2.1 ) . malignant diseases : adult pediatric patients ( 2.2 ) • intravenous : initial course patients hematologic deficiency : 40 mg per kg 50 mg per kg divided doses 2 5 days . regimens include 10 mg per kg 15 mg per kg given every 7 10 days 3 mg per kg 5 mg per kg twice weekly . • oral : 1 mg per kg per day 5 mg per kg per day initial maintenance dosing . minimal change nephrotic syndrome pediatric patients ( 2.3 ) • oral : 2 mg per kg daily 8 12 weeks ( maximum cumulative dose 168 mg per kg ) . treatment beyond 90 days increases probability sterility males . • treatment beyond 90 days increases probability sterility males . ( 8.4 )",
    "warningsAndPrecautions": "cyclophosphamide injection , usp sterile white powder containing cyclophosphamide supplied single-dose vials . cyclophosphamide injection , usp ndc 72572-087-01 500 mg/vial , carton 1 ndc 72572-085-01 1 g/vial , carton 1 ndc 72572-083-01 2 g/vial , carton 1 store vials 25°c ( 77°f ) . transport storage cyclophosphamide vials , temperature influences lead melting active ingredient , cyclophosphamide . [ ( 2.4 ) ] . cyclophosphamide hazardous product . follow special handling disposal procedures.1",
    "adverseReactions": "hypersensitivity cyclophosphamide injection contraindicated patients history severe hypersensitivity cyclophosphamide , metabolites , components product . anaphylactic including death reported cyclophosphamide . cross-sensitivity alkylating agents occur . urinary outflow obstruction cyclophosphamide injection contraindicated patients urinary outflow obstruction [ ( 5.2 ) ] .",
    "indications_original": "Cyclophosphamide for Injection is an alkylating drug indicated for treatment of adults and pediatric patients with: • Malignant Diseases : malignant lymphomas: Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma ( 1.1 ) • Minimal Change Nephrotic Syndrome in Pediatric Patients : biopsy proven minimal change nephrotic syndrome patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy ( 1.2 ) Limitations of Use : The safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established. ( 1.2 )",
    "contraindications_original": "During or immediately after Cyclophosphamide for Injection administration, administer adequate amounts of fluid to reduce the risk of urinary tract toxicity ( 2.1 ). Malignant Diseases: Adult and Pediatric Patients ( 2.2 ) • Intravenous: Initial course for patients with no hematologic deficiency: 40 mg per kg to 50 mg per kg in divided doses over 2 to 5 days. Other regimens include 10 mg per kg to 15 mg per kg given every 7 to 10 days or 3 mg per kg to 5 mg per kg twice weekly. • Oral: 1 mg per kg per day to 5 mg per kg per day for both initial and maintenance dosing. Minimal Change Nephrotic Syndrome in Pediatric Patients ( 2.3 ) • Oral: 2 mg per kg daily for 8 to 12 weeks (maximum cumulative dose 168 mg per kg). Treatment beyond 90 days increases the probability of sterility in males. • Treatment beyond 90 days increases the probability of sterility in males. ( 8.4 )",
    "warningsAndPrecautions_original": "Cyclophosphamide for Injection, USP is a sterile white powder containing cyclophosphamide and is supplied in single-dose vials.\n                  Cyclophosphamide for Injection, USP\n                  \n                     \n                          NDC 72572-087-01 500 mg/vial, carton of 1 NDC 72572-085-01 1 g/vial, carton of 1 NDC 72572-083-01 2 g/vial, carton of 1\n                  \n                  Store vials at or below 25°C (77°F). During transport or storage of cyclophosphamide vials, temperature influences can lead to melting of the active ingredient, cyclophosphamide. [see Dosage and Administration (2.4)]. \n                  Cyclophosphamide is a hazardous product. Follow special handling and disposal procedures.1",
    "adverseReactions_original": "Hypersensitivity\n                     \n                     \n                         Cyclophosphamide for Injection is contraindicated in patients who have a history of severe hypersensitivity reactions to cyclophosphamide, any of its metabolites, or to other components of the product. Anaphylactic reactions including death have been reported with cyclophosphamide. Cross-sensitivity with other alkylating agents can occur.\n                           Urinary Outflow Obstruction\n                        \n                        Cyclophosphamide for Injection is contraindicated in patients with urinary outflow obstruction [see Warnings and Precautions (5.2)]."
}